Home › SEC Filings › Annual Report (10-K)
Annual Report (10-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CELU | 10-K/A | bearish | 5/10 | Celularity Inc. filed an Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive | Oct 20, 2026 |
| PULM | 10-K/A | neutral | 2/10 | Pulmatrix filed an immaterial 10-K/A (Amendment No. 1) solely to correct a typographical error in the date of the Report | Jun 16, 2026 |
| SNSE | 10-K/A | neutral | 3/10 | Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (Business) in response | Jun 2, 2026 |
| ACET | 10-K/A | neutral | 2/10 | Adicet Bio filed an amended 10-K/A to correct an inadvertent omission in Item 9A — the original filing lacked a statemen | May 20, 2026 |
| RNXT | 10-K/A | neutral | 4/10 | RenovoRx filed Amendment No. 1 to its 2025 10-K solely to revise risk factor disclosures (Item 1A) and add missing contr | May 15, 2026 |
| NTHI | 10-K/A | neutral | 3/10 | NeOnc Technologies Holdings filed Amendment No. 1 to its 2025 10-K solely to add Part III information (Items 10-14) that | May 5, 2026 |
| ESLAW | 10-K/A | neutral | 2/10 | Estrella Immunopharma filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executi | Apr 30, 2026 |
| PHGE | 10-K/A | neutral | 3/10 | BiomX filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation, security o | Apr 30, 2026 |
| SCNX | 10-K/A | bearish | 7/10 | Scienture Holdings filed Amendment No. 1 to its 2025 10-K to correct immaterial errors in Item 7 (MD&A) and to include P | Apr 30, 2026 |
| CLRB | 10-K/A | neutral | 2/10 | Cellectar Biosciences filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executi | Apr 30, 2026 |
| VNRX | 10-K/A | neutral | 2/10 | VolitionRx filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III information (directors, executive comp | Apr 30, 2026 |
| SYBX | 10-K/A | neutral | 2/10 | Synlogic filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III items (director/officer info, executive | Apr 30, 2026 |
| RKDA | 10-K/A | neutral | 5/10 | Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details, | Apr 30, 2026 |
| DCOY | 10-K/A | neutral | 2/10 | Decoy Therapeutics filed Amendment No. 1 to its 2025 10-K to include Part III items (directors, executive compensation, | Apr 30, 2026 |
| CYCN | 10-K/A | neutral | 3/10 | This is a routine 10-K/A amendment filed solely to include Part III items (director/officer info, executive compensation | Apr 30, 2026 |
| MDCXW | 10-K/A | neutral | 2/10 | Medicus Pharma Ltd. filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive | Apr 29, 2026 |
| QCLS | 10-K/A | neutral | 2/10 | Q/C Technologies filed Amendment No. 1 to its 2025 10-K solely to add Part III items (director/executive compensation, b | Apr 29, 2026 |
| XBIT | 10-K/A | neutral | 2/10 | XBiotech filed Amendment No. 1 to its 2025 10-K solely to include Part III information (directors, executive compensatio | Apr 29, 2026 |
| NRC | 10-K/A | neutral | 2/10 | NRC Health filed an amended 10-K (Amendment No. 1) solely to provide Part III information—director/officer details, exec | Apr 28, 2026 |
| RNTX | 10-K/A | neutral | 3/10 | Rein Therapeutics filed an amended 10-K to include previously omitted Part III disclosures (Items 10-14) related to dire | Apr 27, 2026 |
| XBIO | 10-K/A | neutral | 3/10 | Xenetic Biosciences filed an amended 10-K to include Part III disclosures (Items 10-14) on directors, executive compensa | Apr 24, 2026 |
| ACLX | 10-K/A | neutral | 2/10 | Arcellx filed an amended 10-K/A to include Part III disclosures (director and executive compensation, ownership, and rel | Apr 24, 2026 |
| JAZZ | 10-K/A | neutral | 4/10 | This is an amended 10-K filing for Jazz Pharmaceuticals that primarily updates Part III to include proxy statement infor | Apr 24, 2026 |
| DAWN | 10-K/A | neutral | 4/10 | This is an amended 10-K filing by Day One Biopharmaceuticals to include Part II and Part III disclosures that were omitt | Apr 17, 2026 |
| QGAI | 10-K/A | neutral | 5/10 | Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) filed an amended 10-K/A to clarify intellectual property ownership | Apr 15, 2026 |
| JUSHF | 10-K/A | neutral | 4/10 | Jushi Holdings filed an amended 10-K to include Part III disclosures (directors, executive compensation, related-party t | Apr 14, 2026 |
| TXMD | 10-K/A | bearish | 5/10 | This is an amended 10-K filing that corrects minor printer errors in the original filing. The amendment does not change | Apr 1, 2026 |
| INVA | 10-K/A | neutral | 3/10 | Innoviva, Inc. filed an amended 10-K to include the audited consolidated financial statements of its majority-owned subs | Mar 27, 2026 |
| SER | 10-K/A | neutral | 2/10 | Serina Therapeutics, Inc. filed an amended 10-K/A solely to correct an incorrect version of the auditor's consent (Exhib | Mar 27, 2026 |
Page 1 of 1